p16Ink4a+ fibroblasts

Biomarker

1 paper2 findings

  • Animals1

Interventions

1

XL888

downin human cells1downin mice1

1 study
  1. XL888 decreases p16Ink4a+ fibroblasts in human cells.

    “reduced p16INK4a+ fibroblasts from IPF PCLS ex vivo.”

    Cellsfrom patients with idiopathic pulmonary fibrosislung

    An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis

    The Journal of clinical investigation7 Mar 2024

  2. XL888 decreases p16Ink4a+ fibroblasts in mice.

    “XL888 treatment eliminated pathogenic p16Ink4a+ fibroblasts in a murine model of lung fibrosis”

    Animalsin a murine model of lung fibrosislung

    An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis

    The Journal of clinical investigation7 Mar 2024

More on XL888

Funding

3 grants since 2022

National Heart, Lung, and Blood InstituteUS$2.5m

Latest

Nov 2025: 1Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 01 in 12 months